Literature DB >> 27816994

BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.

Leanda Vengethasamy1, Aurélie Hautefort2, Birger Tielemans1, Catharina Belge3, Frédéric Perros2, Stijn Verleden1, Elie Fadel4, Dirk Van Raemdonck5, Marion Delcroix3, Rozenn Quarck6.   

Abstract

Mutations in the bone morphogenetic protein receptor (BMPR2) gene have been observed in 70 % of patients with heritable pulmonary arterial hypertension (HPAH) and in 11-40 % with idiopathic PAH (IPAH). However, carriers of a BMPR2 mutation have only 20 % risk of developing PAH. Since inflammatory mediators are increased and predict survival in PAH, they could act as a second hit inducing the development of pulmonary hypertension in BMPR2 mutation carriers. Our specific aim was to determine whether inflammatory mediators could contribute to pulmonary vascular cell dysfunction in PAH patients with and without a BMPR2 mutation. Pulmonary microvascular endothelial cells (PMEC) and arterial smooth muscle cells (PASMC) were isolated from lung parenchyma of transplanted PAH patients, carriers of a BMPR2 mutation or not, and from lobectomy patients or lung donors. The effects of CRP and TNFα on mitogenic activity, adhesiveness capacity, and expression of adhesion molecules were investigated in PMECs and PASMCs. PMECs from BMPR2 mutation carriers induced an increase in PASMC mitogenic activity; moreover, endothelin-1 secretion by PMECs from carriers was higher than by PMECs from non-carriers. Recruitment of monocytes by PMECs isolated from carriers was higher compared to PMECs from non-carriers and from controls, with an elevated ICAM-1 expression. CRP increased adhesion of monocytes to PMECs in carriers and non-carriers, and TNFα only in carriers. PMEC from BMPR2 mutation carriers have enhanced adhesiveness for monocytes in response to inflammatory mediators, suggesting that BMPR2 mutation could generate susceptibility to an inflammatory insult in PAH.

Entities:  

Keywords:  BMPR2; Endothelial cells; Inflammation; Pulmonary arterial hypertension; Smooth muscle cells

Mesh:

Substances:

Year:  2016        PMID: 27816994     DOI: 10.1007/s00424-016-1899-1

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  47 in total

Review 1.  Novel and emerging therapies for pulmonary hypertension.

Authors:  Soni Savai Pullamsetti; Ralph Schermuly; Ardeschir Ghofrani; Norbert Weissmann; Friedrich Grimminger; Werner Seeger
Journal:  Am J Respir Crit Care Med       Date:  2014-02-15       Impact factor: 21.405

Review 2.  Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay.

Authors:  Alice Huertas; Frédéric Perros; Ly Tu; Sylvia Cohen-Kaminsky; David Montani; Peter Dorfmüller; Christophe Guignabert; Marc Humbert
Journal:  Circulation       Date:  2014-03-25       Impact factor: 29.690

3.  Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.

Authors:  Rajiv D Machado; Micheala A Aldred; Victoria James; Rachel E Harrison; Bhakti Patel; Edward C Schwalbe; Ekkehard Gruenig; Bart Janssen; Rolf Koehler; Werner Seeger; Oliver Eickelberg; Horst Olschewski; C Gregory Elliott; Eric Glissmeyer; John Carlquist; Miryoung Kim; Adam Torbicki; Anna Fijalkowska; Grzegorz Szewczyk; Jasmine Parma; Marc J Abramowicz; Nazzareno Galie; Hiroko Morisaki; Shingo Kyotani; Norifumi Nakanishi; Takayuki Morisaki; Marc Humbert; Gerald Simonneau; Olivier Sitbon; Florent Soubrier; Florence Coulet; Nicholas W Morrell; Richard C Trembath
Journal:  Hum Mutat       Date:  2006-02       Impact factor: 4.878

4.  Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice.

Authors:  Yanli Song; John E Jones; Hideyuki Beppu; John F Keaney; Joseph Loscalzo; Ying-Yi Zhang
Journal:  Circulation       Date:  2005-07-18       Impact factor: 29.690

Review 5.  Genetic basis of pulmonary arterial hypertension: current understanding and future directions.

Authors:  John H Newman; Richard C Trembath; Jane A Morse; Ekkehard Grunig; James E Loyd; Serge Adnot; Fabio Coccolo; Carlo Ventura; John A Phillips; James A Knowles; Bart Janssen; Oliver Eickelberg; Saadia Eddahibi; Phillipe Herve; William C Nichols; Gregory Elliott
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

Review 6.  Pulmonary arterial hypertension: evaluation and management.

Authors:  Anne V LaRaia; Aaron B Waxman
Journal:  South Med J       Date:  2007-04       Impact factor: 0.954

Review 7.  Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first.

Authors:  Sylvia Cohen-Kaminsky; Aurélie Hautefort; Laura Price; Marc Humbert; Frédéric Perros
Journal:  Drug Discov Today       Date:  2014-04-18       Impact factor: 7.851

Review 8.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

Review 9.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Florent Soubrier; Wendy K Chung; Rajiv Machado; Ekkehard Grünig; Micheala Aldred; Mark Geraci; James E Loyd; C Gregory Elliott; Richard C Trembath; John H Newman; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

10.  Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.

Authors:  Nicole Pfarr; Justyna Szamalek-Hoegel; Christine Fischer; Katrin Hinderhofer; Christian Nagel; Nicola Ehlken; Henning Tiede; Horst Olschewski; Frank Reichenberger; Ardeschir H A Ghofrani; Werner Seeger; Ekkehard Grünig
Journal:  Respir Res       Date:  2011-07-29
View more
  7 in total

Review 1.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?

Authors:  Rozenn Quarck; Fréderic Perros
Journal:  Stem Cell Investig       Date:  2017-06-14

3.  Cytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in BMPR2-silenced human lung microvascular endothelial cells.

Authors:  Birger Tielemans; Leanda Stoian; Rik Gijsbers; Annelies Michiels; Allard Wagenaar; Ricard Farre Marti; Catharina Belge; Marion Delcroix; Rozenn Quarck
Journal:  Pulm Circ       Date:  2019-10-23       Impact factor: 3.017

4.  Incremental Experience in In Vitro Primary Culture of Human Pulmonary Arterial Endothelial Cells Harvested from Swan-Ganz Pulmonary Arterial Catheters.

Authors:  Birger Tielemans; Leanda Stoian; Allard Wagenaar; Mathias Leys; Catharina Belge; Marion Delcroix; Rozenn Quarck
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

5.  Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series).

Authors:  Wolfgang M Kuebler; Sébastien Bonnet; Arata Tabuchi
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

6.  Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension.

Authors:  Aurélie Hautefort; Julie Chesné; Jens Preussner; Soni S Pullamsetti; Jorg Tost; Mario Looso; Fabrice Antigny; Barbara Girerd; Marianne Riou; Saadia Eddahibi; Jean-François Deleuze; Werner Seeger; Elie Fadel; Gerald Simonneau; David Montani; Marc Humbert; Frédéric Perros
Journal:  Oncotarget       Date:  2017-05-19

Review 7.  Perivascular Inflammation in Pulmonary Arterial Hypertension.

Authors:  Yijie Hu; Leon Chi; Wolfgang M Kuebler; Neil M Goldenberg
Journal:  Cells       Date:  2020-10-22       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.